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Background
The c-Met signaling pathway regulates a variety of biological processes, including proliferation,
survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis
and prognosis of many human malignancies. We studied the function and prognostic signifi-
cance of c-Met and hepatocyte growth factor protein expression in patients with classical
Hodgkin’s lymphoma.
Design and Methods
Expression of c-Met and its ligand, hepatocyte growth factor, were determined by immunohis-
tochemistry. Prognostic values were defined in cohorts of German and Dutch patients with
classical Hodgkin’s lymphoma. Functional studies were performed on Hodgkin’s lymphoma
cell lines. 
Results
Expression of c-Met was detected in the tumor cells of 52% (80/153) of the patients and expres-
sion of its ligand, hepatocyte growth factor, in 8% (10/121) of the patients. c-Met expression
correlated with a 5-year freedom from tumor progression of 94%, whereas lack of expression
correlated with a 5-year freedom from tumor progression of 73% (P<0.001) in the combined
cohort. In multivariate analysis both c-Met (hazard ratio 5.0, 95% confidence interval 1.9-13.3,
P<0.001) and stage (hazard ratio 2.8, 95% confidence interval 1.2-6.4, P=0.014) were independ-
ent predictors for freedom from tumor progression. In functional studies activation with hepa-
tocyte growth factor did not affect cell growth, while the c-Met inhibitor SU11274 suppressed
cell growth by inducing G2/M cell cycle arrest.
Conclusions
Although functional studies showed an oncogenic role of the hepatocyte growth factor/c-Met
signaling pathway in cell cycle progression, expression of c-Met in tumor cells from patients
with classical Hodgkin’s lymphoma strongly correlated with a favorable prognosis in two inde-
pendent cohorts. 
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ABSTRACT
Introduction
Hodgkin’s lymphoma is a B-cell neoplasm characterized
by a minority of neoplastic cells within an extensive infil-
trate of reactive cells. There is a classical form and a nodu-
lar lymphocyte predominant variant. The tumor cells in
classical Hodgkin’s lymphoma (cHL), the so-called
Hodgkin and Reed-Sternberg (HRS) cells, are derived from
pre-apoptotic germinal center B cells that acquire crippling
immunoglobulin gene mutations and/or lose their capaci-
ty to express a high affinity B-cell receptor.1 Epstein-Barr
virus (EBV) infection, constitutive activation of nuclear
factor kB and aberrant activation of receptor tyrosine
kinases contribute to the survival and proliferation of HRS
cells.2,3
The prognosis of cHL patients improved greatly over
the last three decades and current treatment regimens
have reduced treatment failure to less than 20% even in
advanced stages.4 However, long-term toxicities and espe-
cially secondary malignancies are major concerns and the
main challenge in cHL is to avoid overtreatment in indi-
vidual patients. The Ann Arbor staging system is used to
classify cHL into early or advanced stage disease and treat-
ment is tailored accordingly. In addition, several other clin-
icopathological factors are used for risk stratification.5
Although some prognostic tissue markers, such as number
of tumor-infiltrating macrophages,6 HLA class II expres-
sion by tumor cells7 and tumor cell EBV status,8 have been
published, there is currently no pre-treatment cHL prog-
nostic factor that is applied for prediction of treatment
response in a clinical setting.
The hepatocyte growth factor (HGF)/c-Met signaling
pathway regulates a variety of biological processes, includ-
ing proliferation, survival and migration.9 Deregulated c-
Met activation, caused by gene amplification, translocation,
mutation or autocrine/paracrine HGF signaling, has been
implicated in the pathogenesis of many human cancers.10
Furthermore, c-Met is of prognostic significance in numer-
ous malignancies, such as diffuse large B-cell lymphoma,11
bladder cancer,12 breast cancer,13 colorectal cancer14 and ovar-
ian cancer.15 Inhibitors have been developed to target this
signaling pathway and one of these, SU11274,16 shows
effective inhibition of the c-Met signaling pathway, thereby
affecting the survival and growth of lung cancer,17 mesothe-
lioma,18 and melanoma19 cell lines.
c-Met expression has been reported in HRS cells in tis-
sue samples from 33% (6/18)20 and 100% (n=57)21 of cHL
patients. HGF expression was observed in infiltrating cells,
especially in dendritic cells, but not in tumor cells.21
Additionally, both c-Met and HGF are expressed in some
cHL cell lines.22,23 We studied the function of the HGF/c-
Met pathway in cHL cell lines and determined the prog-
nostic value of c-Met expression in two independent
cohorts of patients. 
Design and Methods
Patients and tissue data
Primary cHL tissues were retrieved from the Department of
Pathology, University Medical Center Groningen, the Netherlands
(n=62, collected from 1993 up to 2009) and from the Institute of
Pathology, University of Ulm, Germany (n=91, collected from
1994 up to 2009). 
Almost all patients were treated and staged according to pedi-
atric or adult clinical trial protocols (EORTC or GHSG). The basic
characteristics of the German and the Dutch patients are present-
ed in Table 1. Information on the presence of B symptoms was not
available for two patients and data were lacking on the presence
of bulky disease for four patients; these patients were excluded
from the respective analyses. The International Prognostic Score
(IPS), which incorporates information on age, stage, sex, hemoglo-
bin and albumin levels and leukocyte and lymphocyte counts, was
applied only in patients with advanced stage (stages III and IV).
The IPS was unknown for four patients and these patients were
excluded from the comparisons between c-Met expression and
IPS. No significant differences regarding age at diagnosis, sex, his-
tological subtype, stage of disease and EBV status were observed
between the cohorts. The median follow-up was 61 months for
the German cohort (interquartile range, 39-87 months) and 44
months for the Dutch cohort (interquartile range, 22-83 months).
The German cohort differed significantly from the Dutch cohort
by treatment modality (more German patients received the BEA-
COPP regimen and combined modality treatment was more often
used) (Table 1). The study protocol was consistent with interna-
tional ethical and professional guidelines (the Declaration of
Helsinki and the International Conference on Harmonization
Guidelines for Good Clinical Practice).
Immunohistochemistry 
Immunohistochemistry (IHC) was performed with antibodies
against c-Met (C-28) (Santa Cruz Biotechnology, Santa Cruz, CA,
Table 1. Basic characteristics of the German, Dutch and total combined
cohorts of patients. The P value refers to the difference between the German
and the Dutch patients.
Characteristic All (n = 153) German (n = 91) Dutch (n=62) P value
N. of patients (%) N. of patients (%) N. of patients (%)
Median age (range) 29 (7-75) 29 (8-75) 28(7-66) 0.75
Male 81 (53) 50 (55) 31 (50) 0.62
Histology subtype 0.39
Nodular sclerosis 110 (72) 65 (71) 45 (73)
Mixed cellularity 23 (15) 15 (17) 8 (13)
Lymphocyte rich 3 (2) 3 (3) -
Lymphocyte depleted 1 (1) - 1 (2)
cHL, NOS 16 (11) 8 (9) 8 (13)
EBV status 0.17
Positive 35 (23) 17 (19) 18 (29)
Negative 118 (77) 74 (81) 44 (71)
Ann Arbor stage 0.62
I-II 87 (57) 50 (55) 37 (60)
III-IIV 65 (42) 40 (44) 25 (40)
n.a. 1 (1) 1 (1) -
Treatment: < 0.001
> Combined modality:
ABVD + RT 47 (31) 31 (34) 16 (26)
BEACOPP + RT 16 (11) 16 (18) -
BEACOPP, ABVD + RT 3 (2) 3 (3) -
Pediatric protocols + RT19 (12) 7 (8) 12 (19)
COPP/ABVD + RT 3 (2) 3 (3) -
MOPP/ABV + RT 2 (1) - 2 (3)
> Chemotherapy alone:
ABVD 27 (18) 6 (7) 21 (34)
BEACOPP 27 (18) 24 (26) 3 (5)
MOPP/ABV 7 (5) - 7 (11)
Other 1 (1) 1 (1) -
> Radiotherapy alone 1 (1) - 1 (2)
CHL: classical Hodgkin’s lymphoma, not otherwise specified; n.a.: not available; ¥RT: radiotherapy
(involved field or involved node)
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USA), HGF (R&D Systems, Minneapolis, MN, USA) and CD30
(Dako, Glostrup, Denmark) on paraffin-embedded tissue sections
after antigen retrieval (pH 9). Staining was visualized using horse-
radish peroxidase-labeled secondary antibodies and 3,3'-
diaminobenzidine (Sigma Aldrich, St Louis, MO, USA).
Appropriate positive and negative controls were performed for
each staining. The Dutch cases were stained and scored on a tissue
micro-array (TMA) or on whole tissue sections and the German
cases were scored on whole tissue sections. For c-Met all 153 cases
were stained and for HGF all German cases and the Dutch TMA
were stained (121 cases). Each case in the TMA was represented
by two tissue cores and cases were scored only if at least ten
tumor cells were present in both cores. CD30 expression was used
to identify the tumor cells. The median number of tumor cells for
each case was 30. Only staining of the tumor cells was scored. The
distribution of percentages of c-Met-positive tumor cells showed a
distinction at 30% (20% or less: 72/153 and 30% or more: 80/153).
We hypothesized that this distinction reflects two biologically dif-
ferent subsets and a cut-off of ≥ 30% positive HRS cells was cho-
sen. The percentage of HGF-positive cells for most patients was
10% or less (94/121) and a cut-off of ≥ 20% of positive HRS cells
was chosen.
Cell lines
The cHL cell lines L428, L1236, KMH224 and U-HO125 were cul-
tured in RPMI-1640 medium supplemented with ultraglutamine-
1, 100 U/mL penicillin/streptomycin and 10% fetal calf serum (5%
for the L428 cell line) (Lonza Walkersville, Walkersville, MD,
USA).  
Enzyme-linked immunosorbent assay on 
the supernatant of cultures of classical Hodgkin’s
lymphoma cell lines
Levels of HGF protein were measured in cell culture super-
natants by an enzyme-linked immunosorbent assay according to
the protocol provided by the manufacturer (R&D Systems).
Quantitative reverse transcriptase polymerase 
chain reaction 
RNA was extracted using Trizol® (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. cDNA was made
from 500 ng of total RNA in 20 mL reactions using Superscript II
and random primers (Invitrogen). Two nanograms of cDNA were
used in the quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR) in triplicate using Sybergreen (for HGF) and
probe (for U6), as described by the manufacturer (Applied
Biosystems, Foster City, CA, USA). The primer sequences used for
the amplification were as follows: U6 forward primer: 5’-ttcg-
gcagcacatatactaa-3’ and reverse primer 5’-aatatggaacgcttcacgaa-3’;
U6 probe: 5’-ccctgcgcaaggatgaca-3‘, HGF forward primer (exon 5):
5’-caatccagaggtacgctacgaa-3’ and reverse primer (exon 6) 5’-actctc-
cccattgcaggtcat-3’. U6 was used for normalization (ΔCt = CtHGF -
CtU6). Relative expression levels of HGF were determined using the
formula 2-ΔCt.
Western blot
Cell lysates were separated on polyacrylamide gels and elec-
troblotted onto nitrocellulose membranes using standard proto-
cols. Blots were incubated with primary antibodies, c-Met (C12,
Santa Cruz), p-Met (Tyr1234/1235), p-p44/42 MAPK
(Thr202/Tyr204) (20G11), and p-Akt (Ser473) (D9E) (Cell Signaling
Technology, Boston MA, USA), at 4ºC overnight. Immunostaining
was amplified by incubation with horseradish peroxidase-conju-
gated antibodies and chemiluminescence was detected with ECL
(Pierce, Rockford, USA).  
MTT assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma Aldrich) was added to cells and incubated for 4 h at
37°C. The cells were resolved in dimethylsulfoxide (Sigma
Aldrich) and absorption was measured at 540 nm.
Cell cycle analysis
Hypotonic DNA staining buffer (0.1% sodium citrate; 0.3%
Triton–X 100; 0.01% propidium iodide, 0.002% ribonuclease A)
was added to the cells and mixed well. Data were acquired with a
flow cytometer (Calibur, BD Biosciences, San Jose, CA, USA). 
Definition of endpoints
Freedom from tumor progression (FFTP), and overall survival
were the end-points for this study. FFTP was calculated from the
date of diagnosis until the date of a disease-related event. Disease-
related events were defined as progression during treatment, death
during treatment with unknown disease status, less than a com-
plete remission after treatment and relapse after treatment, includ-
ing death due to lymphoma progression. In case none of these
events occurred, patients were censored at the date of last follow-
up or death. Overall survival was defined as the date of diagnosis
until date of death. In the case of no events, patients were cen-
sored at the date of last follow-up.
Statistical analysis
Fisher’s exact test was used for the analysis of differences in
patients’ characteristics between the German and Dutch cohorts
of patients and between the c-Met-positive and c-Met-negative
patients. Survival curves were computed using the method of
Kaplan and Meier. Differences between the curves were calculated
using the log-rank statistic. Univariate and multivariate Cox logis-
tic regression models were applied to identify prognostic factors
for survival. SPSS statistical software version 18.0 (SPSS Inc.,
Chicago, IL, USA) was used.
Results
c-Met and hepatocyte growth factor expression
in chronic Hodgkin’s lymphoma tissue
Cytoplasmic and membranous c-Met expression in
more than 30% of the tumor cells was observed in 49 out
of 91 German patients (54%) and 31 out of 62 Dutch
patients (50%) (Figure 1A and Online Supplementary Table
S1). Expression was not significantly different between
the two cohorts. Although c-Met expression could be
detected in the reactive cellular background, no specific
pattern of c-Met expression was observed between tumor
cells and infiltrating cells. 
HGF staining in more than 20% of the tumor cells was
detected in 6 out 91 German patients (7%) and 4 out of 30
Dutch patients (13%) (Figure 1B and Online Supplementary
Table S1). Expression was not significantly different
between the two cohorts. Co-expression of c-Met and
HGF in tumor cells was found in only 4 of 121 cHL cases
(3%) (Online Supplementary Table S2). Reactive cells stained
positive in all cHL cases, but no HGF staining was
observed in the lymphocytes directly surrounding the
tumor cells. 
Expression of c-Met (52% positive in the total cohort)
did not correlate with age, sex, histological subtype, stage
of disease, EBV status (Online Supplementary Table S2) or
other known clinical prognostic factors (erythrocyte sedi-
C. Xu et al.
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mentation rate, number of nodal sites, presence of B-
symptoms, bulky disease and IPS). 
Prognostic significance of c-Met expression
In both the German and the Dutch cohorts, c-Met-
positive patients had a significantly more favorable 5-year
FFTP compared to c-Met-negative patients (Figure 2A,B).
Univariate Cox regression analysis in the German cohort
showed that lack of c-Met expression correlated with a
hazard ratio (HR) of 4.2 (P=0.013, 95% CI 1.4-13.2), and
stage with a HR of 4.6 (P=0.008, 95% CI 1.5-14.4). In mul-
tivariate analysis both stage (HR 4.5, P=0.010, 95% CI 1.4-
13.9) and c-Met (HR 3.9, P=0.018, 95% CI 1.3-12.3)
remained independent predictors for FFTP. In the Dutch
c-Met expression predicts a favorable outcome in cHL 
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Figure 1. c-Met and HGF expres-
sion in cHL tissue. (A)
Representative cHL case show-
ing expression of c-Met in HRS
cells (arrow). Expression of c-
Met in the reactive cells can
also be observed. (B)
Representative cHL case show-
ing expression of HGF in HRS
cells (arrows). Reactive cells
were also positive for HGF.
Figure 2. Kaplan-Meier esti-
mates for freedom from tumor
progression (FFTP) and overall
survival (OS) according to c-Met
expression.  c-Met positivity of
HRS cells correlated with very
favorable FFTP in both the
German (A) and the Dutch (B)
cohorts. In the combined
cohort, c-Met expression again
correlated with favorable FFTP
(C) and OS (D) and was inde-
pendent of disease stage (E and
F). Especially among patients
with advanced stage disease
(F), absence of c-Met correlated
with a low 5-year FFTP rate
(57%) compared to the rate in
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cohort only lack of c-Met expression was significant in the
univariate analysis (HR 8.7, P=0.041, 95% CI 1.1-69.9)
(Online Supplementary Table S3). In the combined cohort, c-
Met expression correlated with a 5-year FFTP of 94%,
whereas no expression correlated with a 5-year FFTP of
73% (log rank P<0.001, Figure 2C). Univariate Cox regres-
sion analysis showed that lack of c-Met expression corre-
lated with a HR of 5.1 (P<0.001, 95% CI 1.9-13.5) com-
pared to positive expression (Table 2). Stage was the only
other factor (HR 2.8, P=0.012) that could significantly pre-
dict FFTP. In multivariate analysis both c-Met (HR 5.0,
P<0.001) and stage (HR 2.8, P=0.014) remained independ-
ent predictors for FFTP. Especially in patients with
advanced disease, lack of c-Met expression correlated
with a very poor 5-year FFTP rate (57% versus 91% in c-
Met-positive patients; Figure 2E, F).
In the combined cohort, 5-year overall survival rates
were 98% and 84% for patients expressing or not express-
ing c-Met, respectively (log rank P=0.006, Figure 2D). For
HGF, no significant differences were observed in FFTP and
overall survival.
The c-Met/hepatocyte growth factor signaling pathway
in classical Hodgkin’s lymphoma cell lines
High c-Met expression was only observed in the L428
cell line (Figure 3A). HGF protein levels were high in the
cell culture supernatant of KMH2, with corresponding lev-
els of HGF mRNA (Figure 3B, C). 
Phosphorylated c-Met (p-Met) was present only in the
L428 cell line and stimulation by HGF strongly increased
p-Met levels in this cell line. Low levels of p-Met were
induced in L1236 and U-HO1 (Figure 3D). Analysis of p-
Met downstream substrates in the L428 cell line showed
up-regulation of p-Akt and p-Erk1/2 upon HGF stimula-
tion and this up-regulation was effectively blocked by
SU11274 in a dose-dependent manner (Figure 3E). HGF
stimulation did not affect cell growth (data not shown),
whereas SU11274 significantly suppressed cell growth in a
dose-dependent manner (Figure 3F). This suppression of
cell growth was not caused by an induction of apoptosis
(data not shown). Cell cycle analysis showed that the pro-
portion of cells in the G2/M phase increased from 15% in
control cells to 52% in cells treated with SU11274 (2.5
mM) (P<0.05) (Figure 3G). This effect was greater at a high-
er concentration (5 mM) (data not shown) or after longer
incubation (48 h or 72 h) (Figure 3G), indicating dose- and
time-dependent effects. After 48 h and 72 h a population
of tetraploid cells appeared (Figure 3G).
Discussion
Deregulation of HGF/c-Met signaling has been implicat-
ed in the pathogenesis of many malignancies by disrupting
fundamental biological processes including cell cycle, sur-
vival, adhesion and migration.20,26 In this study, we demon-
strated that c-Met was present in HRS cells in half of the
patients with cHL. In contrast to findings in other malig-
nancies,11-15 positivity of c-Met in the HRS cells was associ-
ated with favorable survival in two different cohorts of
patients. Especially in advanced stage disease, c-Met-
positive patients had a strikingly good FFTP rate (91%)
compared to c-Met-negative patients (57%). This effect on
prognosis appeared to be stronger than the effects that
have been observed for other prognostic tissue markers
such as CD68 (tumor infiltrating macrophages),6 HLA class
II7 and EBV status.8
Expression of c-Met and HGF has been studied previous-
ly in cHL patients and cell lines.20-23 One study showed a
correlation between c-Met expression and EBV-positivity
in a small cohort,20 whereas in a larger study c-Met was
detected in HRS cells of all cHL cases independently of EBV
status.21 We found c-Met expression in more than 30% of
HRS cells in 52% of cHL cases and observed no correlation
with EBV status. The lower percentage of c-Met-positive
cHL cases can be explained by our strict scoring criteria
compared to those used in previous studies. HGF expres-
sion was found in infiltrating cells in cHL tissues, and was
higher in the serum of patients at diagnosis and at relapse
than in the serum of healthy donors and patients in remis-
sion.21 In our study, HGF expression was detected in HRS
cells in a low percentage of cHL cases and in a variable per-
centage of the infiltrating cells in all cases. Co-expression of
HGF and c-Met in HRS cells was found in only 3% of cHL
patients. Paracrine activation of c-Met by HGF might be
involved in the pathogenesis of cHL in c-Met-positive
cases. 
In contrast to our findings, in solid malignancies expres-
sion of c-Met correlates with an unfavorable prognosis.12-15
However, this involves overexpression rather than normal
physiological expression and we found no evidence of
overexpression of c-Met in Hodgkin’s lymphoma.
Although a favorable prognostic impact of c-Met expres-
sion has been shown in a small study on breast cancer27 and
in diffuse large B-cell lymphoma,28 other studies showed
opposite effects for both types of tumors.11,13
To explain the unexpected favorable prognostic impact
of c-Met expression, we studied the functionality of the c-
C. Xu et al.
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Table 2. Univariate and multivariate Cox regression analyses for freedom from tumor progression for c-Met expression and other clinical prognostic
factors in the combined cohort.
Combined cohorts Univariate Multivariate
N. HR 95% CI P HR 95% CI P
c-Met expression < 30% 73 5.1 1.9-13.5 0.001 5.0 1.9-13.3 0.001
Stage III/IV 65 2.8 1.2-6.3 0.014 2.8 1.2-6.4 0.014
IPS ≥ 3 35 2.1 0.7-6.9 0.201
B-symptoms present 70 1.8 0.8-3.0 0.166
Bulky disease 46 0.9 0.7-1.3 0.638
HR: hazard ratio; CI: confidence interval; IPS: International Prognostic Score.
Met/HGF signaling pathway in the cHL cell line L428.
Although p-Met, p-Akt and p-Erk1/2 are strongly up-regu-
lated upon stimulation with HGF, no effect was observed
on cell growth in L428 cells. Nevertheless we did observe
an inhibitory effect on cell growth with c-Met inhibitor
SU11274, which blocked the constitutive phosphorylation
of c-Met and downstream kinases and induced G2/M cell
cycle arrest. 
The stimulating effects of c-Met on cell cycle progression
in L428 cells are inconsistent with the favorable prognostic
value of c-Met positivity in HRS cells in cHL patients. The
unique histological phenotype of cHL might be a key factor
in this unexpected positive prognostic effect. The propor-
tion of tumor cells in cHL is small, typically less than 1%,
and these cells are located within an extensive infiltrate of
reactive cells. In comparison, the proportion of tumor cells
in diffuse large B-cell lymphoma and solid malignancies is
generally between 40% and 80%. When focusing on the
infiltrating cells several known effects of c-Met might
explain the favorable effect of c-Met in Hodgkin’s lym-
phoma. In a rat model of cirrhosis c-Met strongly reduced
liver fibrosis and decreased transforming growth factor-β
(TGF-β) levels.29 Since TGF-β plays an important role in
suppression of an effective immune response in cHL,30 the
activation of c-Met in HRS cells could result in decreased
TGF-β production and, thereby, in enhanced anti-tumor
responses. In monocytes, activation of c-Met induced up-
regulation of pro-inflammatory cytokines31 and a pro-
inflammatory response of the HGF/c-Met pathway was
also found in experimental autoimmune
encephalomyelitis.32 Overall, it can be speculated that acti-
vation of c-Met in HRS cells might alter the immunosup-
pressive properties of the reactive cells by secretion of cer-
tain factors that shape the microenvironment in a way that
c-Met expression predicts a favorable outcome in cHL 
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Figure 3. c-Met and HGF expression and signaling in cHL cell lines. (A) Baseline expression of c-Met was determined in cHL cell lines L428,
KMH2, L1236 and U-HO1. The c-Met level was high in L428, moderate in L1236 and very low to negative in KMH2 and U-HO1. (B) HGF
mRNA levels were measured in cHL cell lines by qRT-PCR. The HGF mRNA level was high in KMH2 and very low in the other three cHL cell
lines. (C) HGF protein levels in the supernatant of cHL cell lines determined by ELISA. The HGF protein level was high in the supernatant of
KMH2 and low to negative in the other three cHL cell lines. (D) p-Met level was compared with or without HGF(R&D systems) stimulation
(100 ng/mL) in cHL cell lines L428, KMH2, L1236 and U-HO1. Without HGF stimulation, constitutive p-Met was only detected in L428. Upon
HGF stimulation, p-Met was strongly up-regulated in L428 and weak to negative in the other three cHL cell lines. (E) Up-regulation of p-Met,
p-Akt and p-Erk1/2 with HGF stimulation could be blocked by the c-Met kinase inhibitor SU11274 (Calbiochem, San Diego, CA, USA) in L428
cells. (F) L428 cells were grown in the presence of increasing concentrations of SU11274 (0, 1, 2.5, 5 mM) for 3 days, and the effect on cell
growth was assayed by MTT. Cell growth at 2.5 mM and 5 mM SU11274 compared with control growth was significantly decreased (P<0.001).
(G) Cell cycle distribution of SU11274 (2.5 mM)-treated L428 cells. Flow cytometry histograms are given with fitted analysis model underly-
ing, in which dark gray areas are calculated areas for cells in G0/G1 and G2 phase and the shaded area is the calculated area for cells in
S phase.  G2/M cell cycle arrest is shown to be an effect of c-Met inhibition. Tetraploid cells with 8N DNA content can be observed after 48
h and 72 h incubation with SU11274.
L428 KMH2 L1236 U-HO1
L428 L1238 U-HO1 KMH2
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is less beneficial for survival and growth of the HRS cells. 
In conclusion, despite its oncogenic function in cHL cell
lines and other malignancies, c-Met expression by tumor
cells in cHL patients predicts a very favorable outcome,
independently of disease stage. Future studies should show
whether c-Met can be used in clinical practice as a pre-
treatment marker to select suitable patients for less toxic
treatment regimens.
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